Published in Leuk Res on February 19, 2010
Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta (2012) 1.89
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway. Leuk Res (2013) 1.60
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res (2014) 1.19
Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal (2012) 1.12
Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PLoS One (2012) 0.77
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer (2015) 0.77
Synthesis and Evaluation of Folate-Conjugated Phenanthraquinones for Tumor-Targeted Oxidative Chemotherapy. Open J Med Chem (2016) 0.75
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Arsenic toxicity and potential mechanisms of action. Toxicol Lett (2002) 3.18
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem (2004) 2.07
How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer (2002) 1.93
Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A (2004) 1.49
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood (2001) 1.36
Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med (2001) 1.25
Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol (2002) 1.21
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia (2003) 1.14
The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol (2004) 1.13
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood (2003) 1.10
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer (2003) 1.09
Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem (2004) 1.06
Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci (2002) 1.05
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia (2003) 1.05
Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma (2002) 0.96
Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta (2003) 0.95
Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood (1992) 0.94
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol (2001) 0.93
Human B lymphocytes show greater susceptibility to H2O2 toxicity than T lymphocytes. J Immunol (1984) 0.93
Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood (2005) 0.91
Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci (1998) 0.88
Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle (2003) 0.88
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med (Berl) (2008) 0.87
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res (2004) 0.86
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist (2003) 0.85
The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol (2003) 0.85
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. Br J Haematol (2002) 0.85
Antioxidant enzymes in lymphocytes from normal subjects and patients with chronic lymphocytic leukaemia: increased glutathione peroxidase activity in CLL B lymphocytes. Br J Haematol (1989) 0.85
Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia. Br J Haematol (2002) 0.83
Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol (2001) 0.83
Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurs (2002) 0.82
Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol (2003) 0.81
Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep (2003) 0.81
Increased glutathione in chronic lymphocytic leukemia lymphocytes. Am J Hematol (1994) 0.80
Influence of controllable lifestyle on recent trends in specialty choice by US medical students. JAMA (2003) 14.06
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Adult Burkitt leukemia and lymphoma. Blood (2004) 3.46
The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003. Acad Med (2005) 3.32
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 2.94
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park) (2012) 2.73
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood (2012) 2.39
Administrative coding data, compared with CDC/NHSN criteria, are poor indicators of health care-associated infections. Am J Infect Control (2008) 2.38
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood (2009) 2.17
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood (2010) 2.07
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2009) 2.06
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Atypical lymphocytic lobular panniculitis. J Cutan Pathol (2004) 2.02
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
A comparison of normalization techniques for microRNA microarray data. Stat Appl Genet Mol Biol (2008) 1.82
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.73
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol (2014) 1.65
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
In-hospital treatment of obstructive sleep apnea during decompensation of heart failure. Chest (2009) 1.63
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood (2012) 1.63
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood (2003) 1.61
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol (2009) 1.61
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol (2003) 1.59
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell (2012) 1.52
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res (2004) 1.52
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res (2007) 1.52
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood (2007) 1.51
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 1.51
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med (2003) 1.51
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res (2013) 1.51